股本结构
单位：万股
| 公告日期 | 2026-09-24 | 2026-08-26 | 2026-08-19 | 2026-08-26 | 2026-08-26 | 2026-06-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 135.32 | 70.66 | 67.76 | 677.58 | 570.02 | 516.94 |
| 普通股本 | 5412912.00 | 2826342.76 | 2710322.00 | 2710322.00 | 2280088.76 | 2067753.20 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 0.10 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-23 | 2026-08-23 | 2026-08-21 | 2026-08-20 | 2026-06-30 | 2026-06-10 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：40000
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-09-24 | 5412912.00 | 未披露 | 定期报告 | 2026-09-23 |
| 2026-08-26 | 2826342.76 | 未披露 | 定期报告 | 2026-08-23 |
| 2026-08-26 | 2710322.00 | 未披露 | 定期报告 | 2026-08-20 |
| 2026-08-26 | 2280088.76 | 0.10 | 定期报告 | 2026-06-30 |
| 2026-06-15 | 2067753.20 | 未披露 | 定期报告 | 2026-06-10 |
| 2026-05-08 | 1583916.80 | 未披露 | 定期报告 | 2026-05-05 |
| 2026-06-15 | 1414195.56 | 0.10 | 定期报告 | 2026-03-31 |
| 2026-04-01 | 1387289.96 | 0.10 |
更多>>
From January 1, 2025 to December 31, 2025
Vested RSU’s
Exercise of prefunded warrant
Issuance of ordinary shares
|
2025-12-31 |
| 2025-11-13 | 1387289.96 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-09-22 | 1275071.56 | 未披露 | 定期报告 | 2025-09-17 |
| 2025-09-11 | 1260887.20 | 0.10 | 定期报告 | 2025-09-11 |
| 2025-09-02 | 605662.36 | 0.10 | 定期报告 | 2025-06-30 |
| 2025-05-07 | 399967.56 | 未披露 | 定期报告 | 2025-03-31 |
| 2025-03-04 | 373471.60 | 0.10 | 定期报告 | 2025-03-03 |
| 2025-03-04 | 373471.82 | 未披露 | 定期报告 | 2025-02-28 |
| 2024-11-25 | 341198.36 | 0.10 | 定期报告 | 2024-09-30 |
| 2024-07-08 | 335431.40 | 未披露 | 定期报告 | 2024-07-01 |
| 2024-08-15 | 334943.16 | 未披露 |
更多>>
From January 1, 2024 to June 30, 2024
Issuance of warrants and shares, net of issuance costs of $275
Vested RSU’s
|
2024-06-30 |
| 2024-07-15 | 216034.68 | 未披露 | 定期报告 | 2024-03-31 |
| 2024-05-15 | 185717.00 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of warrants and shares, net of issuance costs of $86
Shares issued for services
Exercise of warrants
Vested RSU’s
|
2023-12-31 |
| 2023-11-02 | 174077.08 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-09-19 | 189077.08 | 未披露 |
更多>>
ADSs offered 400,000 ADSs representing 160,000,000 Ordinary Shares by the company
|
2023-09-19 |
| 2023-09-19 | 173077.08 | 未披露 | 定期报告 | 2023-09-15 |
| 2023-08-24 | 145376.14 | 未披露 | 定期报告 | 2023-08-24 |
| 2023-08-18 | 146077.08 | 未披露 | 定期报告 | 2023-07-31 |
| 2023-08-11 | 145397.08 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-05-15 | 131362.32 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Exercise of warrants
Vested RSU's
|
2023-03-31 |
| 2023-04-17 | 98929.08 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of shares, net of issuance costs of $129,000
Share-based compensation
Exercise of warrants
|
2022-12-31 |
| 2022-12-20 | 91423.08 | 未披露 |
更多>>
1.Units offered by the company in the offering 400,000 units
|
2022-12-20 |
| 2022-12-20 | 75423.08 | 未披露 | 定期报告 | 2022-12-08 |
| 2022-11-10 | 75423.08 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-08-25 | 74715.31 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-06-03 | 74504.85 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-01-26 | 73904.85 | 未披露 | 定期报告 | 2021-12-29 |
| 2021-02-11 | 57328.58 | 未披露 |
更多>>
1.BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the underwriter of its recent follow-on underwritten offering fully exercised its over-allotment option to purchase 365,217 of BiondVax’s American Depositary Shares (“ADS”).
|
2021-02-10 |
| 2021-02-02 | 55867.71 | 未披露 |
更多>>
1.ADSs offered by the company in the offering 2,434,783 ADSs, representing 97,391,320 Ordinary Shares.
2.The number of Ordinary Shares to be outstanding immediately after the offering, as shown above, is based on 461,085,824 Ordinary Shares outstanding as of September 30, 2020.
|
2021-02-02 |
| 2021-05-13 | 46128.58 | 未披露 | 定期报告 | 2020-12-31 |
| 2021-02-01 | 46108.58 | 未披露 | 定期报告 | 2020-09-30 |
| 2020-08-24 | 46082.26 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-06-12 | 45414.54 | 未披露 | 定期报告 | 2020-05-15 |
| 2020-07-01 | 41021.40 | 未披露 | 定期报告 | 2020-03-31 |
| 2020-06-12 | 45414.54 | 未披露 | 定期报告 | 2019-12-31 |
| 2019-11-26 | 40235.17 | 未披露 | 定期报告 | 2019-09-30 |
| 2019-08-28 | 26175.41 | 未披露 | 定期报告 | 2019-06-30 |
| 2017-11-30 | 26141.96 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-31 | 17959.52 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 17571.58 | 未披露 | 定期报告 | 2017-04-28 |
| 2016-12-12 | 13509.74 | 未披露 | 定期报告 | 2016-12-12 |
| 2016-11-04 | 12003.40 | 未披露 | 定期报告 | 2016-11-01 |
From January 1, 2025 to December 31, 2025
Vested RSU’s
Exercise of prefunded warrant
Issuance of ordinary shares
From January 1, 2024 to June 30, 2024
Issuance of warrants and shares, net of issuance costs of $275
Vested RSU’s
From December 31, 2022 to December 31, 2023
Issuance of warrants and shares, net of issuance costs of $86
Shares issued for services
Exercise of warrants
Vested RSU’s
ADSs offered 400,000 ADSs representing 160,000,000 Ordinary Shares by the company
From January 1, 2023 to March 31, 2023
Exercise of warrants
Vested RSU's
From December 31, 2021 to December 31, 2022
Issuance of shares, net of issuance costs of $129,000
Share-based compensation
Exercise of warrants
1.Units offered by the company in the offering 400,000 units
1.BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the underwriter of its recent follow-on underwritten offering fully exercised its over-allotment option to purchase 365,217 of BiondVax’s American Depositary Shares (“ADS”).
1.ADSs offered by the company in the offering 2,434,783 ADSs, representing 97,391,320 Ordinary Shares.
2.The number of Ordinary Shares to be outstanding immediately after the offering, as shown above, is based on 461,085,824 Ordinary Shares outstanding as of September 30, 2020.